Why the study?
The cholinergic system has nephroprotective effects, but the impact of anticholinergic medications on CKD progression remains unexplored.
Does a high anticholinergic burden increase the risk of CKD progression to kidney replacement therapy in patients with chronic kidney disease?
Does a high anticholinergic burden increase the risk of CKD progression to kidney replacement therapy in patients with chronic kidney disease?
A high anticholinergic burden is associated with a significantly increased risk of progression to kidney replacement therapy in patients with chronic kidney disease.
Answers are grounded in this paper and cite their sources.
High anticholinergic burden may warrant medication review in CKD; leaves open whether deprescribing slows progression to KRT.
Introduction: The cholinergic system exerts nephroprotective effects through antiinflammatory and vasoregulatory pathways. However, the impact of anticholinergic medications on chronic kidney disease (CKD) progression remains unexplored. This study aimed to evaluate the association between anticholinergic burden and CKD progression to kidney replacement therapy (KRT). Methods: ) were enrolled in the Chronic Kidney Disease - Renal Epidemiology and Information Network (CKD-REIN) prospective cohort study. CKD progression (defined as the initiation of KRT) were recorded prospectively during the 5-year follow-up period. For each patient, anticholinergic burden was determined by summing the Anticholinergic Cognitive Burden (ACB) scores of all prescription drugs at baseline. We used multivariable, cause-specific, Cox proportional hazards regression models to analyze the association between anticholinergic burden and CKD progression. Results: ), 647 initiated KRT and 405 died during a median follow-up period of 5 years. A high anticholinergic burden was independently associated with CKD progression (hazard ratio [HR] = 1.53, 95% confidence interval [CI] = 1.09-2.14), relative to a null burden. A low or moderate anticholinergic burden was associated with an elevated risk (HR [95% CI] = 1.09 [0.85-1.24]), although not significantly. Conclusion: A high anticholinergic burden was associated with a greater risk of CKD progression. This finding suggests that the disruption of cholinergic signaling could contribute to a decline in renal function and highlights the importance of medication review and medication optimization in CKD management.
No takes yet. Share an insight, caveat, or question.
Mouheb et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: